Results 41 to 50 of about 22,494 (197)

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Turkish Journal of Hematology, 2015
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi   +7 more
doaj   +1 more source

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. [PDF]

, 2013
PurposeDasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose ...
Chen, Tai-Tsang, Hochhaus, Andreas, Kantarjian, Hagop M, Roy, Amit, Shah, Neil P, Wang, Xiaoning   +5 more
core   +2 more sources

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Jurnal Penyakit Dalam Indonesia, 2020
Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis.
Ikhwan Rinaldi, Ary Harryanto Reksodiputro   +1 more
doaj   +1 more source

The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines [PDF]

, 2012
Purpose Our aim was to evaluate the potential effect of imatinib mesylate (IM), a small molecule that specifically inhibits the tyrosine quinase receptors, on the proliferation and invasive abilities of two human retinoblastoma (Rb) cell lines ...
Antecka, E., Burnier, M. N., Di Cesare, S., Fernandes, B. F., Marshall, J-C, Moura, L. R. de   +5 more
core   +2 more sources

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

OncoImmunology, 2018
Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB,
Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias   +12 more
doaj   +1 more source

Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report

Veterinární Medicína, 2019
A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem.
Joong Hyun Song, Tae Sung Hwang, Hee Chun Lee, Do Hyeon Yu, Byung Joon Seung, Jung Hyang Sur, Dong In Jung   +6 more
doaj   +1 more source

Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia

Eurasian Journal of Medicine, 2019
Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak, Harika Celebi, Aynur Albayrak, Esra Saribacak Can, Vedat Aslan, Birgul Onec, Ipek Coban   +6 more
doaj   +1 more source

Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients [PDF]

, 2010
Background: Adequate surgery still remains the only curative treatment of chordoma. Interesting clinical data on advanced disease with molecularly targeted therapies were reported.Methods: We described the clinical outcome of a series of chordoma ...
Virginia Ferraresi, Carmen Nuzzo, Carmine Zoccali, Ferdinando Marandino, Antonello Vidiri, Nicola Salducca, Massimo Zeuli, Diana Giannarelli, Francesco Cognetti, Roberto Biagini, A Jemal, R Chugh, CE Peña, JM Mirra, NL Higinbotham, C Catton, PW Chambers, S Boriani, F Tzortzidis, D Baratti, D Schulz-Ertner, DC Weber, GF Fleming, E Tamborini, S Stacchiotti, H Hof, K Schönegger, ZL Gokaslan, HY Zhang, P Bergh, KL Foweraker, PA Forsyth, BJ Cummings, P Gabriele, GC Feigl, HD Suit, M Austin-Seymour, M Austin-Seymour, G Noël, R Chugh, PG Scimeca, A Azzarelli, PG Casali, PG Casali, PM Weinberger, S Stacchiotti   +45 more
core   +1 more source

Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects

Animal Models and Experimental Medicine, EarlyView.
Pivotal multifactorial animal models for translational dry eye disease research. Abstract Dry eye disease (DED) is a prevalent and complex multifactorial ocular surface disorder, leading to significant visual discomfort and diminished quality of life.
Jinshen Liu, Jiaqi Chen, Zhonghui Li, Jiamin Zhou, Hui Zhang, Yujia Yu, Feng Cheng, Jie Bao, Chunhan Feng, Xiangqu Yu, Zhao Xia, Rao Ding, Xiang Li   +12 more
wiley   +1 more source